Ideally a patient’s response to neoadjuvant chemotherapy could be observed noninvasively, in the first 2-3 weeks of treatment using an imaging to provide feedback related to the effectiveness of the chosen chemotherapy regimen. This capability would permit individuation of patient care by supporting the opportunity to tailor chemotherapy to a each patient’s response. Functional diffusion mapping (fDM), now called Parametric Response Mapping (PRM) has been proposed as an MRI imaging biomarker for quantifying early brain tumor response to therapy [1-3]. This approach quantifies local apparent diffusion coefficient (ADC) changes in tumors using a voxel-based analysis implemented by rigid registration of the patient’s head between interval exams. The RIDER Breast MRI data set extended this approach by demonstrating ADC changes in 3 of 5 primary breast cancer patients measured in response to onset of neoadjuvant chemotherapy from interval exams separated by only 8-11 days. |